Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Peginterferon Alfa-2a
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 10, 2025
Lead Product(s) : Peginterferon Alfa-2a
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Erythropoietin Alfa
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 09, 2025
Lead Product(s) : Erythropoietin Alfa
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Vietstar Biomedical Research | Clinical Research Consultants, Inc. | Clinical Research Viet Nam Skill Training And Consulting
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Vietstar Biomedical Research | Clinical Research Consultants, Inc. | Clinical Research Viet Nam Skill Training And Consulting
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : NNG-DEPO
Product Type : Protein
Upfront Cash : Inapplicable
October 19, 2022
Lead Product(s) : Darbepoetin alfa
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Faceptor
Product Type : Antibody
Upfront Cash : Inapplicable
March 29, 2022
Details : Undisclosed
Product Name : Faceptor
Product Type : Antibody
Upfront Cash : Inapplicable
March 29, 2022
Lead Product(s) : Nanocovax
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : The Translational Health Science and Technology Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Details : THSTI has entered into a research collaboration with Nanogen Pharmaceutical, which is developing a new vaccine for COVID-19 named Nano Covax which is the first Covid-19 vaccine to be approved by Vietnam’s Ministry of Health to conduct clinical trial in...
Product Name : Nanocovax
Product Type : Vaccine
Upfront Cash : Undisclosed
September 27, 2021
Lead Product(s) : Nanocovax
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : The Translational Health Science and Technology Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Nanocovax
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 11, 2021
Lead Product(s) : Nanocovax
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nanocovax
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 24, 2020
Lead Product(s) : Nanocovax
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.
Details : Undisclosed
Product Name : Pegcyte
Product Type : Protein
Upfront Cash : Inapplicable
December 22, 2017
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable